Dayana Denegri-Hinostroza

Ms. Dayana Denegri-Hinostroza

SCHOOL OF MEDICINE, Universidad Peruana de Ciencias Aplicadas, Lima, Peru
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2025 in Viruses
Verified
Journal Article
Open access
PDF file
EVEliezer Isaí Bonifacio Velez de Villa
Eliezer Isaí Bonifacio Velez de Villa
DADeysi Aguilar-Luis
Deysi Aguilar-Luis
DDDayana Denegri-Hinostroza
Dayana Denegri-Hinostroza
MLMiguel Angel Aguilar Luis
Miguel Angel Aguilar Luis
WCWilmer Gianfranco Silva Caso
Wilmer Gianfranco Silva Caso
LVLuis J. del Valle
Luis J. del Valle
Background: The HPV16 E2 gene plays a crucial role in viral replication and oncogene regulation. This study aimed to assess the genetic variability of the E2 gene and to identify immunogenic epitopes of the E2 protein. Methods: The E2 gene was amplified and sequenced. T-cell epitope prediction and evaluation were performed using IEDB, NetMHCpan v4.0, NetMHCIIpan v4.1, VaxiJen, ToxNet, and pLM4Alg. Results: Phylogenetic analysis of 47 E2 sequences demonstrated co-circulation of the D (n = 4) and A (n = 43) HPV16 lineages in Cajamarca. Twenty-eight Single Nucleotide Polymorphism (SNPs) were identified in E2, 21 of which were nonsynonymous. Seventeen variations were associated with positive Papanicolaou (Pap) test results. Epitope prediction identified 2 MHC class I and 27 MHC class II epitopes classified as potentially antigenic, non-toxic, and non-allergenic, with an overall global population coverage across both MHC classes of 99.78%. Conclusions: The A HPV16 lineage predominated among the women studied. The identified SNPs indicate substantial variability in the E2 gene and a relationship with endocervical lesions. In total, 29 E2-derived T-cell epitopes with immunogenic potential were identified.

16 March 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
WCWilmer Gianfranco Silva Caso
Wilmer Gianfranco Silva Caso
GPGiancarlo Pérez-Lazo
Giancarlo Pérez-Lazo
MLMiguel Angel Aguilar Luis
Miguel Angel Aguilar Luis
AMAdriana Morales-Moreno
Adriana Morales-Moreno
JBJosé Ballena-López
José Ballena-López
JVJuana del Valle-Mendoza
Juana del Valle-Mendoza
Acinetobacter baumannii has been described as a cause of serious community-acquired infections in tropical countries. Currently, its implications when simultaneously identified with other pathogens are not yet adequately understood. A descriptive study was conducted on hospitalized patients with a diagnosis of moderate/severe SARS-CoV-2-induced pneumonia confirmed via real-time RT-PCR. Patients aged > 18 years who were admitted to a specialized COVID-19 treatment center in Peru were selected for enrollment. A. baumannii was detected via the PCR amplification of the blaOXA-51 gene obtained from nasopharyngeal swabs within 48 h of hospitalization. A total of 295 patients with COVID-19 who met the study inclusion criteria were enrolled. A. baumannii was simultaneously identified in 40/295 (13.5%) of COVID-19-hospitalized patients. Demographic data and comorbidities were comparable in both Acinetobacter-positive and -negative subgroups. However, patients identified as being infected with Acinetobacter were more likely to have received outpatient antibiotics prior to hospitalization, had a higher requirement for high-flow nasal cannula and a higher subjective incidence of fatigue, and were more likely to develop Acinetobacter-induced pneumonia during hospitalization. Conclusions: The group in which SARS-CoV-2 and A. baumannii were simultaneously identified had a higher proportion of fatigue, a higher frequency of requiring a high-flow cannula, and a higher proportion of superinfection with the same microorganism during hospitalization.

13 May 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
EVEliezer Isaí Bonifacio Velez de Villa
Eliezer Isaí Bonifacio Velez de Villa
MLMiguel Angel Aguilar Luis
Miguel Angel Aguilar Luis
WCWilmer Gianfranco Silva Caso
Wilmer Gianfranco Silva Caso
LBLorena Becerra-Goicochea
Lorena Becerra-Goicochea
YTYordi Tarazona-Castro
Yordi Tarazona-Castro
LVLuis J. del Valle
Luis J. del Valle
Background: HPV16 is the most prevalent high-risk genotype associated with cervical cancer, yet the genetic variability and immune potential of the replication protein E1 are less characterized in asymptomatic infections. We assessed HPV16 E1 diversity and predicted conserved T-cell epitopes. Methods: We conducted a descriptive cross-sectional study of cervical samples from women undergoing HPV screening. HPV was detected with universal primers and then HPV16-specific PCR. Thirty HPV16-positive samples underwent full-length E1 amplification and nanopore amplicon sequencing. Variability and phylogeny were analyzed with Clustal Omega and MEGA (maximum likelihood). MHC class I and II epitopes were predicted with the IEDB using HLA alleles representative of South American populations and evaluated for conservation, toxicity, allergenicity, and population coverage. Results: Mutations were detected in 14/30 samples, while 16 sequences matched the reference (GenBank: NC_001526.3). European lineages (A1–A3) predominated, with one sequence in the Asian-American lineage D. Seven highly conserved MHC I epitopes and 37 conserved MHC II epitopes were identified. Epitopes mapped to multiple regions across the E1 sequence. Predicted global coverage was 94.38% for MHC I, 83.75% for MHC II, and 99.09% combined. Conclusions: HPV16 E1 is highly conserved and contains candidate T-cell targets with broad predicted coverage, supporting evaluation for future vaccine or immunotherapy strategies.